Report: Shopko launches personalized prescription program
Shopko’s pharmacy is introducing a new prescription synchronization program, AlignMyMeds, that allows prescriptions to be synchronized for automatic refills each month. (Waushara Argus)
PrescribeWellness and Pleio partner on GoodStart program
IRVINE, Calif. — PrescribeWellness is teaming up with Pleio and its GoodStart program to offer patients education and counseling.
“Our new partnership with Pleio and the GoodStart program will add an additional enhancement to the adherence solutions we already provide,” said Mindy Smith, VP of Pharmacy Practice Innovation at PrescribeWellness. “Pleio has proven to instill lasting behavior change in patients through artfully scripted, non-clinical conversations with GoodStart Mentors, and seamless integration with retail pharmacists.”
GoodStart uses a number of approaches that focus on helping patients establish a good medication routine by shaping behavior through goal setting and patient empowerment designed to develop overall health habits. The program helps patients to take their meds as directed, and refill their prescriptions when expected. Through this partnership, the PrescribeWellness affiliated pharmacies can benefit from a patient-centric program that addresses the challenging demands of 5 Star adherence and Pay for Performance measures, while further cementing their relationship with their patients.
“We are excited about the opportunity to partner with PrescribeWellness to deliver our adherence support services via their growing national pharmacy network,” says Mark Connors, CEO of Pleio. “Through this partnership, 14 million patients will receive greater health and wellness support as we integrate the best in class offering of Prescribe Wellness and Pleio.”
Prasco to distribute Teva’s generic of Adderall XR capsules
CINCINNATI — Prasco Laboratories has entered into agreements with Teva and Shire to acquire the rights to distribute the generic version of Adderall XR Extended Release Capsules.
As a result of this acquisition, Prasco will market an AG version of Adderall XR Capsules, CII in the United States that is therapeutically equivalent and substitutable for prescriptions written for Adderall XR, a CNS stimulant that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
The Authorized Generic of Adderall XR is being divested by Teva as a precondition to its pending acquisition of Allergan's generics business. Upon closing of its transaction with Teva, Prasco will immediately take over the distribution of the product, providing a seamless transition for both customers and patients.
"We are pleased to offer consumers an Authorized Generic of Adderall XR, thus allowing physicians, pharmacists, and consumers to experience product continuity between the brand and Prasco's therapeutically-equivalent AG version of Adderall XR," said Prasco CEO Chris Arington.